On April 1, 2018, the prices of nearly 70 generic drugs will be reduced by 25 to 40 per cent across Canada. This drug pricing initiative is the result of a collaboration through the pan-Canadian Pharmaceutical Alliance (pCPA) with the Canadian Generic Pharmaceutical Association (CGPA) to significantly reduce the prices of some of Canada’s most commonly prescribed generic drugs. Canada expects to save up to $385 million in the first year, and up to $3 billion over the next five years through a combination of price reductions, new generic drugs, and prohibiting tendering by participating drug plans (over the five-year term).
Search
Health Systems and Policy Monitor (HSPM)
An innovative platform that provides a detailed description of health systems and provides up-to-date information on reforms and changes that are particularly policy relevant.
For detailed information on country policy responses to the COVID-19 pandemic during 2020-2021, see our separate COVID-19 Health Systems Response Monitor (HSRM).
Updates
New Canadian Drug Pricing Initiative promises significant savings
11 March 2018 | Country Update
Authors
- Matthew Charles Farr
- Husayn Marani
- Greg Marchildon
Country
Subscribe to our newsletter
Sign Up